ஆய்வு ப்ரோக்ர்யாம் ஆஃப் ஆரோக்கியம் கனடா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tetra Bio-Pharma Receives Second Compliant Rating on Inspection from Health Canada Key milestone in the development path to commercialization of Reduvo OTTAWA, ON / ACCESSWIRE / April 1, 2021 / Tetra Bio-Pharma Inc. ( Tetra or the Company ) (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have received a notice of compliance for its Drug Establishment License (DEL) following an audit by the Drug GMP Inspection Program of Health Canada. Guy Chamberland, CEO and CRO of Tetra Bio-Pharma stated, This is a critical step in the regulatory process for drug approval. Tetra s robust GMP quality management system is in place to ensure product quality and consumer safety. This Compliance rating signifies that we are one step closer to our goal of bringing Reduvo soft gel capsules to market in 2021.

Natalie lerouxTetra bio pharma incInspection program of health canadaQuantum pharma incHealth canada foodHealth canadaRegulation services providerTetra bio pharmaDrug establishment licenseQuantum pharmaNew drug submissionReduvo soft gelDrug identification numberநடாலி லேரௌுக்ஷடெட்ரா உயிர் பார்மா இன்க்ஆய்வு ப்ரோக்ர்யாம் ஆஃப் ஆரோக்கியம் கனடா